
Proceedings of the WFH’s Sixth Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia
Year: 2016
Language: Polish
Author(s): World Federation of Hemophilia
Format: Document
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese
This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for the translation or for any errors or changes to content from the original English edition. Patient organizations interested in translating a WFH resource must first obtain permission from the WFH, available here.
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia

Also Available In: Japanese A national tender is a cost-effective system for the purchase of products or services, such as

A comprehensive guide to creating and maintaining a successful contract fractionation program, from contract agreements to the fractionation process, the

Describes the manufacturing methods and characteristics of hemostatic products and their clinical indications for patients suffering with disorders.

This monograph outlines the treatment protocol used by healthcare providers in Georgia, U.S.A., as an example of a strategy to

Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese 国ごとの国家入札制度は、凝固因子製剤等の製品やサービスを購入するコスト効率の高い制度で、治療用製剤の需要や使用量の予測を促進し、より高水準な治療を可能にします。